Funahara Y, Shirahata A, Harun S R, Setiabudy-Dharma R, Nathin M A, Karjomanggolo T W, Tamaela L A
Department of Physiology, Kobe University School of Medicine, Japan.
Southeast Asian J Trop Med Public Health. 1987 Sep;18(3):356-61.
Patients diagnosed clinically as having grade II dengue haemorrhagic fever, and confirmed serologically to have been recently infected by dengue virus were randomly assigned to two groups, to assess suppression of plasma leakage by intravenous administration of carbazochrome sodium sulfonate(AC-17). The double-blind prospective study over three successive epidemic periods included 39 patients in the placebo group, and 38 in the AC-17 group. The effects of the administration were evaluated with respect to pleural effusion of the chest X-ray films. A clear difference between the two groups was found in the numbers of patients with pleural effusion and severity of the pleural effusion thus the administration of AC-17 may be useful in eliminating the risk factors of severe bleeding and shock in dengue haemorrhagic fever.
临床上诊断为II级登革出血热且血清学确诊近期感染登革病毒的患者被随机分为两组，以评估静脉注射卡巴克络磺酸钠（AC - 17）对血浆渗漏的抑制作用。在连续三个流行期进行的双盲前瞻性研究中，安慰剂组有39例患者，AC - 17组有38例患者。根据胸部X光片上的胸腔积液情况评估给药效果。两组在胸腔积液患者数量和胸腔积液严重程度方面存在明显差异，因此AC - 17给药可能有助于消除登革出血热严重出血和休克的危险因素。
